BiotechTube
Amoeba S.A.

Amoeba S.A.

ALMIB.PAPre-clinical
11-50 employeesamoeba-biocide.com

Amoeba S.A. leverages its proprietary amoeba-based platform to create novel biocontrol agents targeting major agricultural pests and exploring applications in human health. The company's lead candidate, Lys Amoéba, is a biocontrol fungicide/bactericide derived from Willaertia magna C2c Maky, aimed at reducing chemical pesticide use in agriculture. Amoeba is a publicly traded company focused on providing sustainable, biological alternatives in the growing agri-tech market, with its research and development operations based in Chassieu, France.

Market Cap
$72.0M
-16.9% period
Pipeline
—
Patents
—
Publications
—

ALMIB.PA · Stock Price

USD 0.910.18 (-16.88%)

Historical price data

AI Company Overview

Amoeba S.A. leverages its proprietary amoeba-based platform to create novel biocontrol agents targeting major agricultural pests and exploring applications in human health. The company's lead candidate, Lys Amoéba, is a biocontrol fungicide/bactericide derived from Willaertia magna C2c Maky, aimed at reducing chemical pesticide use in agriculture. Amoeba is a publicly traded company focused on providing sustainable, biological alternatives in the growing agri-tech market, with its research and development operations based in Chassieu, France.

Agriculture (Biocontrol)Infectious Diseases

Technology Platform

Platform based on the amoeba Willaertia magna C2c Maky, which produces a lysate (Lys Amoéba) with multi-target biocidal activity against pathogenic fungi and bacteria, primarily for crop protection.

Funding History

2
Total raised:$20M
IPO$15MJul 3, 2018
Grant$5MJun 15, 2016

Opportunities

The global shift towards sustainable agriculture and the phasing out of chemical pesticides creates a massive tailwind for effective biocontrol solutions like Lys Amoéba.
Its novel, multi-target mechanism offers a solution to pest resistance, a key differentiator.
Successful market entry could position the company for acquisition or as a standalone leader in the biologicals niche.

Risk Factors

The company faces significant regulatory risk pending approval from EU and other authorities.
As a pre-revenue entity, it is dependent on future capital raises and faces commercialization risks against established competitors.
Scaling production and achieving farmer adoption present additional execution challenges.

Competitive Landscape

Amoeba competes with large agrochemical firms (Bayer, BASF, Syngenta) and pure-play biocontrol companies. Its differentiation lies in the novel origin and multi-modal action of its Willaertia magna-based product, which may offer efficacy against resistant strains and a favorable environmental profile compared to conventional chemicals.